ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Omega 3 in Hemodialysis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00431899
Recruitment Status : Completed
First Posted : February 6, 2007
Last Update Posted : March 3, 2016
Sponsor:
Information provided by:
Laboratoire Régional de Nutrition Humaine

Brief Summary:
The aim of the study was to determine the effects of a 3-week fish oil oral supplementation on the metabolic fate and thermogenic effect of an oral glucose load in hemodialysis patients.

Condition or disease Intervention/treatment Phase
Hemodialysis End Stage Renal Disease Behavioral: fish oil supplementation Not Applicable

Study Type : Interventional  (Clinical Trial)
Enrollment : 8 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Effets of Fish Oil on Metabolic Fate of an Oral Glucose Load in Patients With End Stage Renal Disease Undergoing Hemodialysis
Study Start Date : May 2003
Study Completion Date : November 2003

Resource links provided by the National Library of Medicine

Drug Information available for: Fish oil
U.S. FDA Resources




Primary Outcome Measures :
  1. plasma glucose utilization
  2. glucose-induced thermogenesis


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • hemodialysis at least 6 months duration end stage renal disease

Exclusion Criteria:

  • - Age < 18 y ou > 75 y
  • Hemodialysis < 6 months
  • Diabetes, obesity
  • allergy to fish
  • Asthma
  • glucocorticoïds, propranolol,, Immunosuppressive drugs, Insulin, Somatostatin
  • erythropoïetin < 3 months
  • Cancer
  • Hemoglobin < 11 g/l
  • disease < 1 month
  • pregnancy
  • respiratory insufficiency
  • intensive sport practice
  • refusal

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00431899


Locations
France
Laboratoire Régional de Nutrition Humaine
Brest, France, F-29200
Sponsors and Collaborators
Laboratoire Régional de Nutrition Humaine
Investigators
Principal Investigator: Jacques Delarue, MD,PhD CHU Cavale Blanche F-29200 Brest

ClinicalTrials.gov Identifier: NCT00431899     History of Changes
Other Study ID Numbers: HDW3
First Posted: February 6, 2007    Key Record Dates
Last Update Posted: March 3, 2016
Last Verified: February 2007

Keywords provided by Laboratoire Régional de Nutrition Humaine:
nutrition
omega 3 fatty acids
insulin resistance

Additional relevant MeSH terms:
Kidney Diseases
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency